TY - JOUR
T1 - Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans
AU - Macefield, V. G.
AU - Williamson, P. M.
AU - Wilson, L. R.
AU - Kelly, J. J.
AU - Gandevia, S. C.
AU - Whitworth, J. A.
N1 - Funding Information:
This study was supported by the National Health and Medical Research Council of Australia. Haematology and biochemistry services were provided by Southpath, courtesy of the Division of Medicine, St George Hospital.
PY - 1998/7
Y1 - 1998/7
N2 - Aim: This study was undertaken to test the hypothesis that increased sympathetic vasomotor drive is responsible for cortisol-induced hypertension. Methods: Ten healthy male subjects on a fixed sodium diet (150 mmol/day) were randomized to five days of treatment with cortisol (200 mg/day) or placebo in a double-blind crossover study. On day 5 of each treatment, multi-unit muscle sympathetic activity was recorded from the common peroneal nerve. Resting muscle sympathetic activity (MSA) was measured in the recumbent position and stimulated MSA was measured in the final 20 sec of end-inspiratory capacity apnoea and end-expiratory apnoea and in the second minute of a cold pressor stimulus. A subgroup of six subjects also underwent identical MSA measurements following 5 days treatment with dexamethasone (3 mg/day). Major findings: Cortisol, but not placebo, significantly increased systolic (115 ± vs 129 ± 3 mmHg precortisol vs cortisol day 5, p < 0.001) and diastolic blood pressure (53 ± 3 vs 61 ±, p < 0.05). Resting MSA was significantly reduced by cortisol (23.9 ± 2.3 to 5.0 ± 2.0 bursts/min, placebo vs cortisol, p < 0.01). Cortisol significantly attenuated the increase in MSA observed at end-inspiratory apnoea (56.3 ± 3.9 vs 35.4 ± 6.6, p < 0.05) and end-expiratory apnoea (50.5 ± 3.5 vs 26.3 ± 6.2 bursts/min, n = 8, p < 0.05), and during the cold pressor response (55.0 ± 12.7 vs 21.4 ± 7.6, n = 5, p < 0.05). Dexamethasone significantly increased systolic blood pressure and suppressed resting and stimulated MSA. No changes in body weight, haematocrit or angiotensin II concentrations occurred during dexamethasone treatment. Conclusion: MSA is significantly suppressed by cortisol treatment. As suppression of MSA is also observed during treatment with the pure glucocorticoid dexamethasone, suppressed MSA cannot be attributed to increased plasma volume or to changes in angiotensin II concentration. We conclude that cortisol-induced hypertension is not due to increased muscle sympathetic vasomotor drive.
AB - Aim: This study was undertaken to test the hypothesis that increased sympathetic vasomotor drive is responsible for cortisol-induced hypertension. Methods: Ten healthy male subjects on a fixed sodium diet (150 mmol/day) were randomized to five days of treatment with cortisol (200 mg/day) or placebo in a double-blind crossover study. On day 5 of each treatment, multi-unit muscle sympathetic activity was recorded from the common peroneal nerve. Resting muscle sympathetic activity (MSA) was measured in the recumbent position and stimulated MSA was measured in the final 20 sec of end-inspiratory capacity apnoea and end-expiratory apnoea and in the second minute of a cold pressor stimulus. A subgroup of six subjects also underwent identical MSA measurements following 5 days treatment with dexamethasone (3 mg/day). Major findings: Cortisol, but not placebo, significantly increased systolic (115 ± vs 129 ± 3 mmHg precortisol vs cortisol day 5, p < 0.001) and diastolic blood pressure (53 ± 3 vs 61 ±, p < 0.05). Resting MSA was significantly reduced by cortisol (23.9 ± 2.3 to 5.0 ± 2.0 bursts/min, placebo vs cortisol, p < 0.01). Cortisol significantly attenuated the increase in MSA observed at end-inspiratory apnoea (56.3 ± 3.9 vs 35.4 ± 6.6, p < 0.05) and end-expiratory apnoea (50.5 ± 3.5 vs 26.3 ± 6.2 bursts/min, n = 8, p < 0.05), and during the cold pressor response (55.0 ± 12.7 vs 21.4 ± 7.6, n = 5, p < 0.05). Dexamethasone significantly increased systolic blood pressure and suppressed resting and stimulated MSA. No changes in body weight, haematocrit or angiotensin II concentrations occurred during dexamethasone treatment. Conclusion: MSA is significantly suppressed by cortisol treatment. As suppression of MSA is also observed during treatment with the pure glucocorticoid dexamethasone, suppressed MSA cannot be attributed to increased plasma volume or to changes in angiotensin II concentration. We conclude that cortisol-induced hypertension is not due to increased muscle sympathetic vasomotor drive.
KW - Cortisol
KW - Dexamethasone
KW - Microneurography
KW - Muscle sympathetic nerve activity
UR - http://www.scopus.com/inward/record.url?scp=0031767056&partnerID=8YFLogxK
U2 - 10.1080/080370598437240
DO - 10.1080/080370598437240
M3 - Article
C2 - 9858113
AN - SCOPUS:0031767056
SN - 0803-7051
VL - 7
SP - 215
EP - 222
JO - Blood Pressure
JF - Blood Pressure
IS - 4
ER -